Siddharth Mittal Appointed as Managing Director and CEO of Syngene International Limited

Siddharth Mittal Appointed as Managing Director and CEO of Syngene International Limited​

Syngene International, a global contract research, development, and manufacturing organization (CRDMO), has announced that Siddharth Mittal has assumed the role of Managing Director and Chief Executive Officer, effective July 1, 2026.

Mittal succeeds Peter Bains, who completed his tenure as Managing Director and CEO on June 30, 2026.

Siddharth brings nearly three decades of business leadership experience to Syngene. He joins the company from Biocon Limited, where he most recently served as the Managing Director and Chief Executive Officer. During his thirteen years at Biocon, Mr. Mittal held the position of Chief Financial Officer before being appointed MD and CEO. In this capacity, he played a critical role in shaping the company's strategic trajectory, expanding its commercial operations globally, securing key regulatory approvals, and successfully commercializing Biocon's GLP-1 portfolio across major international markets. He also led strategic partnerships and commercial initiatives, driving operational excellence and sustainable growth at Biocon.

Kiran Mazumdar-Shaw, Executive Chairperson of Syngene International, commented on the appointment, stating: "I am delighted to welcome Siddharth as the Managing Director and CEO of Syngene. Having worked closely with Siddharth for many years, I have seen firsthand his ability to lead businesses through a period of change, build strong teams, and deliver transformation and sustainable growth."

The Executive Chairperson added that while Syngene has established a reputation for scientific excellence, quality, and customer trust, it is at an inflection point. She expressed confidence that Siddharth's leadership, commercial acumen, and execution focus will help the company unlock its full potential and create long-term value for shareholders, employees, and customers as industry expectations continue to rise.

Commenting on his appointment, Siddharth Mittal said: "I am honoured to take on the role of Managing Director and CEO of Syngene. The company has built exceptional scientific capabilities, a talented team, and gained the trust of customers across the world. These enduring strengths provide a solid platform for driving the next phase of long-term growth."

Mittal outlined his immediate priorities at Syngene: "My immediate priority is to sharpen our commercial edge, strengthen delivery excellence, and bring greater focus and discipline to execution across the business. By combining our scientific strengths and talented workforce with an unwavering focus on customer fulfilment and cost competitiveness, I am confident that we can restore growth momentum and reinforce Syngene's standing as a global leader in CRDMO services, while creating long-term value for all our stakeholders."

About Syngene International Limited​

Syngene International Ltd. is an integrated research, development, and manufacturing services company serving the pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors globally. The company employs over 8,300 individuals, including more than 5,700 scientists. Syngene operates specialized discovery, development, and manufacturing facilities spanning over three million square feet across India and the U.S.

The organization works with approximately 400 global customers across various industry segments, partnering with biotech companies pursuing leading-edge science and multinational corporations such as BMS, GSK, Zoetis, and Merck KGaA.

SYNGENE Stock Price Movement​

Syngene International Limited's equity shed 1.73% on Wednesday after closing at ₹431.55, pulling back from the previous session's close. The stock traded a total of 1,036,500 shares during the session.